García-Martín Antonia, Reyes-García Rebeca, Avila-Rubio Verónica, Muñoz-Torres Manuel
Unidad de Metabolismo Óseo, Servicio de Endocrinología y Nutrición, Hospital Universitario San Cecilio, Granada, Spain.
Endocrinol Nutr. 2013 May;60(5):260-3. doi: 10.1016/j.endonu.2012.06.008. Epub 2012 Dec 4.
Research in animal models has demonstrated the role of osteocalcin, a bone formation marker, in regulation of energy metabolism. Those studies have led to a new concept of the bone acting as an endocrine organ by secreting osteocalcin, which acts by increasing insulin secretion, lowering plasma glucose, and increasing insulin sensitivity and energy expenditure. Results in humans have been conflicting. On the other hand, antiresorptive drugs used against osteoporosis decrease osteocalcin levels, while anabolic drugs increase osteocalcin levels. However, the effects of these therapies on energy metabolism have not been investigated.
对动物模型的研究已证明骨钙素（一种骨形成标志物）在能量代谢调节中的作用。这些研究催生了一个新的概念，即骨骼作为一个内分泌器官，通过分泌骨钙素发挥作用，骨钙素可增加胰岛素分泌、降低血糖水平、提高胰岛素敏感性并增加能量消耗。人体研究结果存在矛盾。另一方面，用于治疗骨质疏松症的抗吸收药物会降低骨钙素水平，而促合成药物则会提高骨钙素水平。然而，这些疗法对能量代谢的影响尚未得到研究。
